Background
==========

Rapid eye movement (REM) sleep behavior disorder (RBD) is diagnosed when patients present with a clinical history of complex motor dream enactment behaviors during REM sleep and exhibit REM sleep atonia loss on polysomnography (PSG).[@b1-imcrj-12-051]--[@b3-imcrj-12-051] People who suffer from RBD move their limbs or even rise and engage in activities associated with waking. Some patients engage in sleep talking, shouting, screaming or violent movements such as hitting or punching.[@b1-imcrj-12-051]--[@b3-imcrj-12-051] The prevalence of RBD has been estimated to be in the range of 0.5%--2%;[@b1-imcrj-12-051]--[@b3-imcrj-12-051] yet, larger population-based studies of patients with probable dream enactment symptoms suggest that RBD is more common, with an incidence rate between 5% and 13% among community-dwelling individuals aged 60--99 years.[@b4-imcrj-12-051]--[@b7-imcrj-12-051] There is strong evidence suggesting that RBD is linked to the development of neurodegenerative diseases, including Parkinson's disease, Lewy body disease and multiple system atrophy.[@b8-imcrj-12-051]

Some patients with insulinoma present with neuropsychiatric symptoms and are often misdiagnosed as having psychiatric disease.[@b9-imcrj-12-051],[@b10-imcrj-12-051] Patients with hypoglycemia, like those with insulinoma, typically present with neurologic symptoms such as confusion (80%), visual disturbances (59%), amnesia or coma (47%), abnormal behavior (36%) and seizures (17%).[@b11-imcrj-12-051] Here, we report a case of a patient with RBD who was later diagnosed with insulinoma. The patient provided written informed consent after receiving a full description of the study and consented to the publication of the report.

Case presentation
=================

We present a case involving a 72-year-old Japanese female who suffered from hypertension and somatization disorder. She developed daytime sleepiness 1 year prior to hospitalization and had been unsteady on her legs, experiencing twilight state three or four at night and exhibiting violent behavior; she also had daytime amnesia. She was diagnosed with dissociative disorder due to workplace stress and was treated with escitalopram 10 mg/day for 2 months. The symptoms appeared to improve, but after the dose was decreased to 5 mg/day because of nausea, the symptoms recurred. She was examined at our hospital. Her diagnosis was suspected to be RBD or epilepsy rather than dissociative disorder. An electroencephalogram performed on the day she was examined was within normal limits. Brain MRI showed no abnormalities. We prescribed clonazepam 1 mg/day at bedtime. The next morning at 6 am, she was admitted to the emergency room (ER) of our hospital because of her violent behavior. Her injurious disruptive behavior continued in the ER. She was admitted to the psychiatry ward after receiving an intramuscular injection of 25 mg of levomepromazine. Because her blood glucose level was 27 mg/dL (normal range 73--109 mg/dL) in the morning, the patient underwent further biochemical examinations which revealed that her insulin level was 9.1 µU/mL (normal range 0.0--18.7 µU/mL), C-peptide level was 2.16 ng/mL (normal range 0.80--2.50 ng/mL) and her insulin/C-peptide ratio was 4.21. An intravenous one-shot injection of 40 mL of 50% glucose was administered, and her blood glucose level increased to 175 mg/dL, 10 minutes after the injection. The patient's blood glucose level decreased to 36 mg/dL in the afternoon. Her blood glucose level was 38 mg/dL the next morning; therefore, after a consultation with endocrinologists, 5% glucose at a rate of 1,500 mL/24 hours was administered continuously while she was in the hospital. The sleep behavior disorder disappeared after continuous glucose administration. A contrast-enhanced computed tomography revealed a high-density mass, 8 mm in diameter, in the pancreatic head ([Figure 1](#f1-imcrj-12-051){ref-type="fig"}). Her diagnosis was changed from REM sleep behavior disorder to insulinoma. She was moved from the psychiatry ward to the medical ward of the Department of Endocrinology. We performed a 48-hour fasting blood glucose test, although she was not symptomatic. Her 48-hour fasting blood glucose level was 57 mg/dL, serum insulin level was 5.3 µU/mL, C-peptide level was 7.5 ng/mL and her insulin/C-peptide ratio was 3.73. Her glycemic response was 57, 83, 110 and 123 mg/dL at the baseline and 10, 20 and 30 minutes after intravenous injection of glucagon 1.0 mg. Eight weeks after these tests, she was admitted to the Department of Gastroenterological Surgery and she underwent enucleation of the insulinoma. After enucleation of the insulinoma, the administration of glucose was discontinued, and her blood glucose level recovered. She was discharged 3 days after the surgery.

Discussion and conclusion
=========================

This case suggests that it is difficult to distinguish between hypoglycemia and RBD. According to the International Classification of Sleep Disorders-2, RBD is defined as the following: 1) the presence of REM sleep without atonia, which is the sustained or intermittent elevation of submental electromyography (EMG) tone or excessive phasic muscle activity in the limb EMG; 2) at least one of the following: sleep-related injurious or potentially injurious disruptive behaviors documented in the patient's history or abnormal REM sleep behaviors documented on PSG; 3) the absence of epileptiform activity during REM sleep unless RBD can be clearly distinguished from any concurrent REM sleep-related seizure disorder and 4) the absence of a better explanation for the sleep disorder as any other medical, neurologic disorder or mental disorder; medication use; or substance use disorder. Because PSG was not examined, only one of these four criteria was met. After the administration of continuous glucose, her sleep behavior disorder disappeared. In addition, after enucleation of the insulinoma, even when the administration of glucose was discontinued, her symptoms did not reappear. Based on the clinical course, we concluded that her injurious disruptive behavior during sleep was the result of hypoglycemia due to insulinoma and not associated with an RBD.

The major cause of hypoglycemia is the use of oral diabetes agents or insulin, especially in elderly individuals.[@b12-imcrj-12-051] For patients without diabetes, hypoglycemia is the result of hyperinsulinemia. Insulinoma is a neuroendocrine tumor derived from insulin-secreting pancreatic beta cells. The clinical manifestations result from endogenous hyperinsulinism-related hypoglycemia that is identified when plasma glucose concentrations are \<55 mg/dL in nondiabetic individuals.[@b13-imcrj-12-051] Insulinoma is a rare endocrine tumor with an annual incidence of 1--4 in 1,000,000 individuals and can occur at any age.[@b14-imcrj-12-051]--[@b16-imcrj-12-051]

Suzuki et al[@b10-imcrj-12-051] reported three cases of insulinoma masquerading as RBD, which were similar to our case. Interestingly, these three patients had previously received anticonvulsant drugs for suspected epilepsy, but the medications were ineffective. PSG showed no evidence of REM sleep without atonia in any of the three patients. We did not use PSG because hypoglycemia was identified and the administration of glucose was efficacious, so we were able to rapidly reassess her diagnosis. In addition, hypoglycemia can mimic epileptic seizures and can manifest as seizures.[@b17-imcrj-12-051] Patients with hypoglycemia can present with dizziness,[@b18-imcrj-12-051] altered behavior,[@b19-imcrj-12-051] irrelevant speech and delusions.[@b20-imcrj-12-051] Insulinoma presents with various neuroglycopenic manifestations that are reversed by the administration of glucose. Recurrent attacks of hypoglycemia can cause some residual neurologic deficits.[@b21-imcrj-12-051]--[@b24-imcrj-12-051] Clinicians, therefore, should be aware that although insulinomas are rare, they can mimic parasomnias, such as RBD.

Consent for publication
=======================

Written informed consent was obtained from the patient for publication of this case report. The ethics committee of the School of Medicine at Hirosaki University judged that there was no need to review this case.
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All data generated or analyzed during this study are included in this published article.
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